Clinical Medicine Insights: Oncology

Development of Interpretable Predictive Models for BPH and Prostate Cancer

Submit a Paper

Clinical Medicine Insights: Oncology 2015:9 15-24

Original Research

Published on 25 Feb 2015

DOI: 10.4137/CMO.S19739

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Oncology


Background: Traditional methods for deciding whether to recommend a patient for a prostate biopsy are based on cut-off levels of stand-alone markers such as prostate-specific antigen (PSA) or any of its derivatives. However, in the last decade we have seen the increasing use of predictive models that combine, in a non-linear manner, several predictives that are better able to predict prostate cancer (PC), but these fail to help the clinician to distinguish between PC and benign prostate hyperplasia (BPH) patients. We construct two new models that are capable of predicting both PC and BPH.

Methods: An observational study was performed on 150 patients with PSA ≥3 ng/mL and age >50 years. We built a decision tree and a logistic regression model, validated with the leave-one-out methodology, in order to predict PC or BPH, or reject both.

Results: Statistical dependence with PC and BPH was found for prostate volume (P-value < 0.001), PSA (P-value < 0.001), international prostate symptom score (IPSS; P-value < 0.001), digital rectal examination (DRE; P-value < 0.001), age (P-value < 0.002), antecedents (P-value < 0.006), and meat consumption (P-value < 0.08). The two predictive models that were constructed selected a subset of these, namely, volume, PSA, DRE, and IPSS, obtaining an area under the ROC curve (AUC) between 72% and 80% for both PC and BPH prediction.

Conclusion: PSA and volume together help to build predictive models that accurately distinguish among PC, BPH, and patients without any of these pathologies. Our decision tree and logistic regression models outperform the AUC obtained in the compared studies. Using these models as decision support, the number of unnecessary biopsies might be significantly reduced.




BibTex citation   (BIBDESK, LATEX)




What Your Colleagues Say About Clinical Medicine Insights: Oncology
I had a great experience publishing our paper in Clinical Medicine Insights: Oncology. The review was prompt and fair and once it was accepted with the revisions, the editorial office was very clear and helpful with updates on the progress at each step of the publication process.  I had prompt email responses to my questions.  I will definitely try to publish more papers in this journal in the future.  Keep the good work. ...
Dr Jan Moreb (University of Florida, Gainesville, FL, USA)
More Testimonials

Quick Links

New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube